Eisbach Bio Announces First Patient Dosed in Phase 1/2 Trial for EIS-12656, a First-In-Class Allosteric Inhibitor of ALC1 in Refractory Advanced Solid Tumors The first patient has been dosed in Eisbach Bio’s Phase 1/2 MATCH clinical trial at MD Anderson assessing the ALC1 inhibitor EIS-12656 in solid tumors.